Carbocisteine 375mg capsules

Country: যুক্তরাজ্য

ভাষা: ইংরেজি

সূত্র: MHRA (Medicines & Healthcare Products Regulatory Agency)

সক্রিয় উপাদান:

Carbocisteine

থেকে পাওয়া:

Creo Pharma Ltd

এটিসি কোড:

R05CB03

INN (International Name):

Carbocisteine

ডোজ:

375mg

ফার্মাসিউটিকাল ফর্ম:

Oral capsule

প্রশাসন রুট:

Oral

শ্রেণী:

No Controlled Drug Status

প্রেসক্রিপশন টাইপ:

Valid as a prescribable product

পণ্য সারাংশ:

BNF: 03070000; GTIN: 5060222601183

তথ্য লিফলেট

BBBA3995
_Continued over page_
_Continued top of next column_
CARBOCISTEINE 375MG CAPSULES
PACKAGE LEAFLET: INFORMATION FOR THE USER
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU
START TAKING THIS MEDICINE.
• Keep this leaflet. You may need to read it
again.
• If you have any further questions, ask your
doctor or pharmacist.
• This medicine has been prescribed for you
only. Do not pass it on to others. It may
harm them, even if their symptoms are the
same as yours.
• If you get any side effects, talk to your
doctor or pharmacist. This includes any
possible side effects not listed in this
leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1 WHAT CARBOCISTEINE 375MG CAPSULES
ARE AND WHAT THEY ARE USED FOR
2 WHAT YOU NEED TO KNOW BEFORE YOU
TAKE CARBOCISTEINE 375MG CAPSULES
3 HOW TO TAKE CARBOCISTEINE 375MG
CAPSULES
4 POSSIBLE SIDE EFFECTS
5 HOW TO STORE CARBOCISTEINE 375MG
CAPSULES
6 CONTENTS OF THE PACK AND OTHER
INFORMATION
1 WHAT CARBOCISTEINE 375MG CAPSULES
ARE AND WHAT THEY ARE USED FOR
Carbocisteine 375mg Capsules are used to
help treat respiratory tract problems (problems
with the breathing passages) characterised
by too much sticky mucus, including chronic
obstructive airways disease (lung damage with
restricted airways).
Carbocisteine 375mg Capsules contain
carbocisteine which belongs to a group of
medicines called mucolytics which cause the
mucus to be less sticky and easier to cough up.
2 WHAT YOU NEED TO KNOW BEFORE YOU
TAKE CARBOCISTEINE 375MG CAPSULES
DO NOT TAKE CARBOCISTEINE 375MG
CAPSULES IF YOU:
• are ALLERGIC to carbocisteine or any of the
other ingredients of this medicine (listed in
section 6)
• have an ACTIVE PEPTIC (STOMACH) ULCER.
WARNINGS AND PRECAUTIONS
Talk to your doctor if you:
• are ELDERLY
• have a history of STOMACH ULCERS
• are taking medicines that may cause
INTESTINAL BLEEDING
• are PREGNANT or planning to become
pregnant
• are BREAST FEEDING.
OTHER MEDICINES AND CARBOCISTEINE
375MG CAPSULES
Tell your doctor or pharmacist if you are taking,
have recently taken

পণ্য বৈশিষ্ট্য

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Carbocisteine 375 mg Capsules, Hard
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 375 mg carbocisteine
Excipient(s) with known effect
Each Carbocisteine 375 mg Hard Capsule contains 22.5 mg lactose
monohydrate.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Capsule, hard
Yellow cap and yellow body, size ‘0’ hard gelatine capsule, filled
with white
to off white granular powder imprinted with C on cap and 375 on body.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Carbocisteine is a mucolytic agent for the adjunctive therapy of
respiratory
tract disorders characterised by excessive, viscous mucus, including
chronic
obstructive airways disease.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and elderly _
Dosage is based upon an initial daily dosage of 2250 mg carbocisteine
in divided
doses, reducing to 1500 mg daily in divided doses when a satisfactory
response is
obtained e.g. two capsules three times a day reducing to one capsule
four times a day.
_ _
_Paediatric population _
Carbocisteine 375 mg Capsules, hard are not recommended for children.
Method of administration
For oral use.
4.3
CONTRAINDICATIONS
This medicine is contraindicated in case of:
-
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
-
Use in patients with active peptic ulceration.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Caution is recommended in the elderly, in those with a history of
gastroduodenal ulcers, or those taking concomitant medications known
to cause
gastrointestinal bleeding. If gastrointestinal bleeding occurs,
patients should
discontinue medication.
Patients with rare hereditary problems of galactose intolerance, the
Lapp
lactase deficiency or glucose-galactose malabsorption should not take
this
medicine.
4.5
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None stated.
4.6
FERTILITY, PREGNANCY AND LACTATION
Pregnancy
Although tests in